Investors & Media

Corporate Profile

We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.

ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • August 15, 2022
    Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
  • August 1, 2022
    Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
  • July 8, 2022
    Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022


  • July 11 - July 12, 2022

    William Blair Biotech Focus Conference 2022

    Read More
  • June 29, 2022

    Aileron Therapeutics Phase 1b Non-Small Cell Lung Cancer Interim Analysis Conference Call

    Read More

To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of life


To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy